Escala Medical

Escala Medical is developing the first repair device for the treatment of pelvic organ prolapse (POP) based on a nonsurgical, incision-free, mesh-free repair approach. 

The Product & Advantages

Escala’s novel system presents a long-overdue repair option for women with mild to moderate POP. Escala’s approach mirrors a gold standard surgery-based repair to fixate the vaginal apex to the sacrospinous ligament (SSL) in a safe, quick outpatient procedure.

  • Incision- and mesh-free
  • Safe, quick, and easy to perform fixation
  • Restores anatomy and preserves pelvic organ functionality
  • Outpatient (ambulatory) or office-based procedure with minimal hospital stay
  • Reduced complications and minimal patient discomfort

The Team

  • Edit Goldberg, DMD, CEO: Over 15 years of medical device industry experience in senior development and strategic and business development positions. DMD, Hadassah School of Dental Medicine, Hebrew University of Jerusalem; MBA, Interdisciplinary Center (IDC), Herzliya
  • Roger P. Goldberg, MD, MPH, Inventor: Clinical Associate Professor, University of Chicago Pritzker School of Medicine; Director, Division of Urogynecology
  • Douglas S. Scherr, MD, Inventor: Associate Professor of Urology; Clinical Director, Urologic Oncology, Weill Medical College of Cornell University

Trendlines’ directors: Todd Dollinger, Nitza Kardish

Escala Medical CEO Edit Goldberg presents at the China-Israel Technology Innovation Cooperation Forum, Shenzhen and Hebei, 20 May 2018.

Escala Medical CEO Edit Goldberg presents at the China-Israel Technology Innovation Cooperation Forum, Shenzhen and Hebei, 20 May 2018.


Founded: December 2014
Stage: Business development; signed term sheet for investment from a top-20 medtech multinational
Investor: The Trendlines Group
IP: 1 National phase (United States, Brazil, EU, China); PCT (international patent application (filed in the United States)


  • Signed term sheet for investment from a top-20 medtech multinational
  • Successful cadaver studies

In the Media

Background & the U.S. Market

POP is a clinical condition that affects millions of women worldwide. Associated with physical, psychological, and sexual problems, POP has a significant impact on quality of life. Treatment options are limited.

  • Supportive devices (pessaries) provide transient symptom relief but may cause significant complications and discomfort.
  • Invasive repair surgeries (abdominal and transvaginal approaches) involve hospitalization and cause early- and late-stage complications

Surgeons specializing in POP repair are in immediate need of minimally invasive solutions that provide permanent relief of symptoms for the large number of women who are reluctant to use pessaries or undergo surgery.

More than 3.3 million women in the United States are diagnosed with POP. By 2050, it is estimated that the incidence of women with POP will increase by 46%. About 20% undergo surgery for POP (or UI) before the age of 80. Approximately 400,000 surgical repair procedures for POP are performed annually at an estimated direct cost of $1.4 billion.

Escala Medical believes its repair system will increase market potential as a solution for women who may be poor surgical candidates or are reluctant to undergo surgery. The Company estimates the U.S. market opportunity to exceed $600 million.

Major players in the surgical field include Ethicon, Bard, AMS (Endo), Boston Scientific, Coloplast, and Mentor.


Watch the interview with CEO Edit Goldberg on ILTV.

See the company one-page description in Chinese (PDF).

Escala Medical product
See the video of Escala's nonsurgical approach to treat pelvic organ prolapse.


Edit Goldberg, CEO

Escala Medical logo

Font Resize